États-Unis · Plateformes & données · Morningstar

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

Publié par Morningstar · États-Unis il y a 9 h

Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

À lire aussi

Bloom Energy vs. Oracle: Which AI Infrastructure Stock Is the Better Buy After the Jupiter Setback?

SentinelOne Says AI Threat Hunting Boosted Malicious Activity Finds 2,200%

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

Why is Contemporary Amperex Technology stock sliding today?

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

SPCX Stock Jumps Overnight: Musk Teases $1 Trillion Revenue By 2028 — Analyst Sees 95% Tesla Merger Odds In 2 Years

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

Partager

À lire aussi

Bloom Energy vs. Oracle: Which AI Infrastructure Stock Is the Better Buy After the Jupiter Setback?

SentinelOne Says AI Threat Hunting Boosted Malicious Activity Finds 2,200%

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

Why is Contemporary Amperex Technology stock sliding today?

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

SPCX Stock Jumps Overnight: Musk Teases $1 Trillion Revenue By 2028 — Analyst Sees 95% Tesla Merger Odds In 2 Years